Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib in Idiopathic Pulmonary Fibrosis
NCT02168530Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Oct 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of vismodegib in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Planned start Oct 2014; status: withdrawn.
02
Drugs
vismodegib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02168530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168530.